Effects of Pioglitazone and Irbesartan on Endothelial Dysfunction on Experimentally Streptozotocin-Induced Diabetic Nephropathy in Rats

Table 2: Effects of irbesartan (IRB), pioglitazone (PIO), and their combination on renal blood flow (RBF) and lipid peroxidation (MDAp) in diabetic rats.


Parameters Groups	Renal blood flow (ml/min.) Mean ± SE	MDAp (µmol/ml) Mean ± SE

Control	11.4 ± 0.9	3.2 ± 0.31
DM group	2.3 ± 0.15 ^a	7.11 ± 0.31 ^a
Irbesartan-treated	6.5 ± 0.39 ^b	5.13 ± 0.19 ^b
Pioglitazone-treated	7.1 ± 0.45 ^b	5.6 ± 0.41 ^b
IRB+PIO high dose treated	9.9 ± 0.40 ^{b c d}	4.1 ± 0.29 ^{b c d}
IRB+PIO low dose treated	10.1 ± 0.46 ^{b c d}	4.51 ± 0.23 ^{b c d}

^aSignificant difference from control group.
^bSignificant difference from diabetic group.
^cSignificant difference from irbesartan group.
^dSignificant difference from pioglitazone group.